March is the awareness month for both Colorectal and Kidney Cancers. Colorectal cancer (commonly known as colon cancer) is symbolized by a dark blue ribbon, while an orange ribbon is the symbol for kidney cancer awareness.
As the region’s largest, most comprehensive provider of clinical research and drug trials, New York Oncology Hematology would like to make you aware of clinical research trials related to these cancers.
We are currently participating in a colon cancer trial: 12091 BT-CL-PGG-CRC1031. For more information about this or any other trial, please visit our Research and Clinical Trials page or call the NYOH Research Department at: (518) 489-0044 ext. 1239
More information about colon and kidney cancer:
According to the American Cancer Society, colon cancer is the third most common cancer in the US and third leading cause of death. However, death rates are dropping, thanks to improvements in prevention, early detection and treatment.
Kidney cancer is among the top ten most common cancers in the US, with higher rates for men and both men and women over age 55. While kidney cancer has been on the rise since the late 1990s, this is likely the result of improved imaging and testing. Death rates have gone down during this same period.
Below is additional information from the American Cancer Society:
Cancer Research at NYOH
Working with the US Oncology Network, National Cancer Institute, Dana Farber Cancer Institute and private pharmaceutical companies, New York Oncology Hematology provides the largest, most comprehensive clinical trial operation in the region. Trials are administered to patients across NYOH’s offices.
Over the past twenty years, NYOH has played a pivotal role in the FDA approval process of 24 new anticancer drugs. NYOH is proud to participate in nearly 50 clinical trials for a range of cancers. Visit our Research and Clinical Trials page to learn more or search trials for a specific cancer or call the NYOH Research Department at: (518) 489-0044 ext. 1239.
New York Oncology Hematology – when experience matters most.